Medicine and Dentistry
Acute Myeloid Leukemia
46%
Graft Versus Host Reaction
42%
Overall Survival
41%
Chronic Graft Versus Host Disease
41%
Cord Blood
38%
Cord Blood Stem Cell Transplantation
32%
Hematopoietic Stem Cell
30%
Alternative Donor
30%
Granulocyte Colony Stimulating Factor
28%
Transplantation
28%
Cell Transplantation
27%
Hematopoietic Stem Cell Transplantation
27%
Acute Graft Versus Host Disease
27%
Progenitor Cell
24%
Myelodysplastic Syndrome
24%
Serositis
24%
Placental Growth Factor
24%
Hematologic Malignancy
21%
Immunosuppressive Treatment
17%
Human Leukocyte Antigen
17%
Hematopoiesis
16%
Tumor Necrosis Factor
15%
Angiogenic Factor
14%
Bone Marrow Failure
14%
Allograft
14%
Amphiregulin
13%
DNA Methyltransferase 3A
13%
Toll Like Receptor
12%
Recurrence Risk
12%
Pericarditis
12%
Lung Function Test
12%
Cost Benefit Analysis
12%
Cytarabine
12%
Chronic Myelogenous Leukemia
12%
Cytarabine Plus Daunorubicin
12%
Liposomal Daunorubicin
12%
Liver Transplantation
12%
CD22 Antigen
12%
Lung Function
12%
Stromal Cell
12%
Mesenchymal Stem Cell
12%
Proteomics
12%
Hemophagocytosis
12%
Allotransplantation
12%
Secondary Acute Myeloid Leukemia
12%
Mononuclear Phagocyte
12%
Infusion
10%
Risk Stratification
9%
Clinical Trial
9%
Cumulative Incidence
9%
Keyphrases
Graft-versus-host Disease (GvHD)
100%
Acute Myeloid Leukemia
49%
Clinical Trials Network
38%
Marrow Transplantation
36%
Angiogenic Factors
28%
Transplant Outcomes
27%
Overall Survival
22%
Hematopoietic Cell Transplantation
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
18%
Follistatin
16%
Leukemia Patients
15%
Hematological Malignancies
15%
Epidermal Growth Factor
15%
Disease Progression
15%
Bone Marrow Failure
14%
Myelodysplastic Syndrome
14%
Placental Growth Factor (PlGF)
14%
Clinical Outcomes
14%
Clonal Hematopoiesis of Indeterminate Potential
13%
Amphiregulin
13%
Non-relapse Mortality
12%
Need to Know
12%
Cord Blood Transplantation
12%
European LeukemiaNet
12%
Feasibility Analysis
12%
Minnesota
12%
Pharmacokinetics
12%
Hematologist
12%
Clonal Hematopoiesis
12%
Donor-derived
12%
Liver Transplantation
12%
Chronic Myeloid Leukemia
12%
Tumor Necrosis Factor-α
12%
Cell Secretome
12%
Disease Risk Prediction
12%
Phase 1 Trial
12%
High-risk Myelodysplastic Syndrome
12%
Functional Screening
12%
Double Cord Blood Transplant
12%
CPX-351
12%
Calreticulin Gene
12%
Severe Acute
12%
Immunosuppressive Therapy
12%
Renal Function Decline
12%
Polymorphism
12%
Allotransplantation
12%
Hematopoietic Stem Cell Transplantation
12%
Interleukin-1β
12%
Adverse Impact
12%
Late Acute
12%
Immunology and Microbiology
Acute Graft Versus Host Disease
54%
Transplant Procedure
46%
Hematopoietic Cell
46%
Chronic Graft Versus Host Disease
41%
Angiogenic Factor
34%
Graft-Versus-Host Disease
34%
Cord Blood Stem Cell Transplantation
31%
Cell Transplantation
30%
Placental Growth Factor
28%
Overall Survival
22%
Allotransplantation
15%
Tumor Necrosis Factor
15%
Endoglin
13%
Amphiregulin
13%
Chimera
13%
Interleukin 1
12%
Myeloid
12%
CD3 Antigen
12%
Mediator
12%
Leukocyte
12%
Mononuclear Phagocyte
12%
Pericarditis
12%
Inflammation Response
12%
Hematopoiesis
12%
Umbilical Cord Blood
12%
Immunosuppressive Therapy
12%
Natural Killer Cell
12%
Lymphocytopenia
12%
Toll-Like Receptor
12%
CXCL10
12%
CXCR3
12%
Lung Function
12%
Monocyte
10%
Engraftment
10%
Human Leukocyte Antigen
9%
Blood Plasma
7%
Epidermal Growth Factor
7%
Hematopoietic Stem Cell Transplantation
7%
Lymphocyte
6%
CD34
6%
Conditioning
5%
Monocyte Count
5%
Stem Cell
5%